Gaudium IVF & Women Health Ltd launched its Initial Public Offering (IPO) on February 20, 2026. It enters the second day of bidding today and the bidding window for the Gaudium IVF & Women Health IPO will remain open till February 24, 2026.

Gaudium IVF and Women Health known for providing in vitro fertilisation (IVF) treatment and reproductive healthcare services in India.The allotment date for the IPO is finalised as February 25, 2026 and the tentative listing date is fixed as February 27, 2026. The shares of Gaudium IVF & Women Health Ltd will be listed on both NSE and BSE.

Gaudium IVF & Women Health IPO - Issue Details

Gaudium IVF & Women Health IPO is a bookbuild issue of ₹165.00 crores and is a combination of fresh issue of 1.14 crore shares aggregating to ₹90.00 crores and offer for sale (OFS) of 0.95 crore shares aggregating to ₹75.00 crores.

The IPO price band is set between ₹75 to ₹79 per share and the minimum lot size for an application is 189. The minimum investment required by the retail individual investors (RIIs) is ₹14,175.

Sarthi Capital Advisors Private Limited is the book-running lead manager for the IPO and Bigshare Services Private Limited is the registrar.

Gaudium IVF & Women Health IPO Day 2 Subscription Status

[February 23, 2026, 11:30 A.M.]

On Day 2, Gaudium IVF & Women Health IPO saw a subscription of 1.75 times as per NSE data on February 23, 2026, 11:30 am. The public issue was subscribed 2.51 times by the Retail Individual Investors (RIIs), 2.28 times by the Non Institutional Investors (NIIs) and 0.01 times by the Qualified Institutional Buyers (QIBs).

Explore other Upcoming IPOs on BSE and NSE.

Utilisation of IPO Proceeds

The net proceeds from the fresh issue will be used towards the following purposes:

Funding capital expenditure towards establishment of New IVF Centers of the Company.
Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company.
General Corporate Purposes.

Check out newly Listed IPOs on BSE and NSE.

Gaudium IVF & Women Health Ltd GMP

As per media reports, the Grey Market Premium (GMP) of Gaudium IVF & Women Health Ltd is reported at ₹8.50 or 11% over the upper end of the price band.

Gaudium IVF & Women Health Ltd - Business Overview

Gaudium IVF & Women Health Ltd is a Delhi-based healthcare company founded in March 2015 by Dr. Manika Khanna. It specialises in fertility and women’s health services, offering treatments such as In Vitro Fertilization (IVF), ICSI, IUI, genetic testing (PGT), male infertility care, and high-risk pregnancy support through a hub-and-spoke network of clinics across India.

The company operates over 30 centres, including 7 hub centres and 28 spoke units providing advanced assisted reproductive technologies and comprehensive women’s health care in major cities. In FY25 (year ended March 31, 2025), the company reported a revenue of about ₹70.96 crore, up from ₹48.15 crore in FY24, and profit after tax (PAT) of around ₹19.13 crore, nearly doubling year-on-year.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here

Do you like this edition?